Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Accured Expenses (2018 - 2025)

TransMedics has reported Change in Accured Expenses over the past 8 years, most recently at $7.0 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $7.0 million for Q4 2025, up 199.74% from a year ago — trailing twelve months through Dec 2025 was $17.7 million (up 122.9% YoY), and the annual figure for FY2025 was $17.7 million, up 122.9%.
  • Change in Accured Expenses for Q4 2025 was $7.0 million at TransMedics, down from $13.1 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for TMDX hit a ceiling of $13.1 million in Q3 2025 and a floor of -$4.6 million in Q1 2025.
  • Median Change in Accured Expenses over the past 5 years was $2.2 million (2021), compared with a mean of $2.4 million.
  • Biggest five-year swings in Change in Accured Expenses: surged 86450.0% in 2023 and later plummeted 9377.55% in 2025.
  • TransMedics' Change in Accured Expenses stood at $2.5 million in 2021, then surged by 36.76% to $3.4 million in 2022, then soared by 44.93% to $5.0 million in 2023, then crashed by 53.45% to $2.3 million in 2024, then soared by 199.74% to $7.0 million in 2025.
  • The last three reported values for Change in Accured Expenses were $7.0 million (Q4 2025), $13.1 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.